Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03931408
Recruitment Status : Recruiting
First Posted : April 30, 2019
Last Update Posted : April 30, 2019
Sponsor:
Information provided by (Responsible Party):
April Herrity, University of Louisville

Brief Summary:
Participants will undergo daily gentamicin bladder instillations to determine if its use will reduce the rate of symptomatic urinary tract infections (UTIs) as well as the use of oral and intravenous antibiotics in adults with chronic spinal cord injury (SCI) who have recurrent UTIs. Participants are randomized into one of three groups: 1) Gentamicin and saline instillation 2) Saline only instillation 3) Standard of care, no instillation.

Condition or disease Intervention/treatment Phase
Neurogenic Bladder Spinal Cord Injuries Drug: Gentamicin Sulfate Other: Placebo instillation (saline alone) Other: No instillation Phase 2

Detailed Description:
The purpose of this study is to determine if twice daily bladder flushing with an antibiotic solution will decrease the rate of UTIs and the use of oral medications used to treat UTIs. The occurrence of UTIs in the SCI population is high, with a rate of about 2.5 episodes per year. The inability to effectively empty the bladder increases the risk of UTIs, which are the most common medical complication after SCI. This study will help us understand the effectiveness of a local bladder therapy on preventing UTIs and improving bladder function in individuals with SCI.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Before the intervention, you will be randomly assigned to one of three groups.
Primary Purpose: Prevention
Official Title: The Evaluation of Antimicrobial Bladder Instillation on the Prevalence of Chronic Urinary Tract Infections and Bladder Dysfunction in Persons With Spinal Cord Injury
Actual Study Start Date : February 19, 2019
Estimated Primary Completion Date : January 16, 2021
Estimated Study Completion Date : January 16, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Gentamicin
Participants will be randomized into one of three groups. In this arm, participants will perform bladder instillations using a 60ml solution of gentamicin mixed with saline, 2 times per day. A formulation derived from 480 mg gentamicin sulfate diluted in 1 L normal saline will be used for instillation. Participants will be blinded during the study and will not know if they are receiving gentamicin or placebo (saline alone).
Drug: Gentamicin Sulfate
Gentamicin will be compounded for immediate use in single-dose, disposable BD 60ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
Other Name: Gentamicin only

Placebo Comparator: Placebo instillation (saline alone)
Participants will be randomized into one of three groups. In this arm, participants will perform bladder instillations using a 60ml solution of saline alone. Participants will be blinded during the study and will not know if they are receiving gentamicin or placebo (saline alone).
Other: Placebo instillation (saline alone)
Saline will be compounded for immediate use in single-dose, disposable BD 60ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
Other Name: Saline only

No instillation
Participants will be randomized into one of three groups. In this arm participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
Other: No instillation
Participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.




Primary Outcome Measures :
  1. Incidence of urinary tract infections measured with Urinalysis and Culture [ Time Frame: Change from Baseline urinary tract infections to post intervention, an average of 5 months. ]
    Assessment of symptomatic urinary tract infection

  2. Presence of abnormal ranges of complete cell counts measured by an 8ml blood draw. [ Time Frame: Change from Baseline blood draw values to post intervention, an average of 5 months. ]
    Assessment of complete blood count.

  3. Evaluate bladder storage using Urodynamics [ Time Frame: Change in Baseline bladder capacity to post intervention, an average of 5 months. ]
    Assessment of lower urinary tract function: Change in Baseline bladder capacity (mL) to post intervention

  4. Evaluate bladder emptying via measurements of voiding efficiency (%) via Urodynamics assessment or uroflow (if appropriate). [ Time Frame: Change in Baseline voiding efficiency to post intervention, an average of 5 months. ]
    Assessment of lower urinary tract function.

  5. Presence of bladder and kidney anatomical and morphological changes measured with Ultrasound. [ Time Frame: Change in Baseline ultrasound outcomes to post intervention, an average of 5 months. ]
    Assessment of upper and lower urinary tract

  6. Prevalence of different bladder management techniques, such as medication usage, measured by SCI data set Questionnaires. [ Time Frame: Change in Baseline bladder management to post intervention, an average of 5 months. ]
    Questionnaires to assess bladder management outcomes

  7. Rate of urinary tract infections measured by SCI data set Questionnaires. [ Time Frame: Change in Baseline urinary tract infections to post intervention, an average of 5 months. ]
    Questionnaires to rate of urinary tract infections. (Note there is no scale as a component of this questionnaire.)

  8. Presence of abnormal ranges of metabolic markers measured by an 8ml blood draw for a comprehensive metabolic panel. [ Time Frame: Change from Baseline blood draw values to post intervention, an average of 5 months. ]
    Assessment of metabolic parameters.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age;
  • Non-progressive spinal cord injury;
  • Stable medical condition;
  • Bladder dysfunction as a result of spinal cord injury
  • History of recurrent UTIs (defined as 3 or more within the past year or 2 or more within the past 6 months).

Exclusion Criteria:

  • Signs or symptoms of serious UTI that requires the use of systemic antibiotics;
  • Use of any urine-acidifying agent, bladder irrigant, or systemic antibiotic within the previous 2 weeks;
  • Participants colonized with gentamicin-resistant bacteria on baseline urine culture or a gentamicin allergy/sensitivity;
  • Participants with known hearing loss and/or renal disease;
  • Pregnant at the time of enrollment or planning to become pregnant during the time course of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03931408


Contacts
Layout table for location contacts
Contact: April Herrity, PhD (502) 587-4461 AprilHerrity@catholichealth.net

Locations
Layout table for location information
United States, Kentucky
Frazier Rehab Recruiting
Louisville, Kentucky, United States, 40202
Contact: April Herrity, PhD    502-587-4461    AprilHerrity@catholichealth.net   
Sponsors and Collaborators
University of Louisville

Layout table for additonal information
Responsible Party: April Herrity, Assistant Professor, University of Louisville
ClinicalTrials.gov Identifier: NCT03931408     History of Changes
Other Study ID Numbers: 18.0586
First Posted: April 30, 2019    Key Record Dates
Last Update Posted: April 30, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by April Herrity, University of Louisville:
bladder
spinal cord injury
urinary tract infection

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Wounds and Injuries
Spinal Cord Injuries
Urinary Tract Infections
Urinary Bladder, Neurogenic
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Urologic Diseases
Neurologic Manifestations
Urinary Bladder Diseases
Signs and Symptoms
Pharmaceutical Solutions
Gentamicins
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action